Protein kinase inhibitors and cancer targeted therapy

Hekmat, Azadeh; Saboury, Ali Akbar

doi:10.1016/b978-0-323-91287-7.00022-3

Cited by 1 publication

(1 citation statement)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The synthesis of Abemaciclib Mesylate commences with the condensation of ABEM-1 with acetyl chloride in the presence of potassium carbonate, yielding the resultant ABEM-2 (Scheme 22). ABEM-2 is subsequently treated with ABEM-3 in the presence of POCl 3 and TEA, yielding ABEM-4 [118]. The cyclization of ABEM-4 in the presence of t-BuOK leads to the formation of ABEM-5.…”

Section: Abemaciclib Mesylatementioning

confidence: 99%

Catalysts of Healing: A Symphony of Synthesis and Clinical Artistry in Small-Molecule Agents for Breast Cancer Alleviation

Hu,

Zhu,

Niu

2024

Molecules

View full text Add to dashboard Cite

Breast cancer, characterized by its molecular intricacy, has witnessed a surge in targeted therapeutics owing to the rise of small-molecule drugs. These entities, derived from cutting-edge synthetic routes, often encompassing multistage reactions and chiral synthesis, target a spectrum of oncogenic pathways. Their mechanisms of action range from modulating hormone receptor signaling and inhibiting kinase activity, to impeding DNA damage repair mechanisms. Clinical applications of these drugs have resulted in enhanced patient survival rates, reduction in disease recurrence, and improved overall therapeutic indices. Notably, certain molecules have showcased efficacy in drug-resistant breast cancer phenotypes, highlighting their potential in addressing treatment challenges. The evolution and approval of small-molecule drugs have ushered in a new era for breast cancer therapeutics. Their tailored synthetic pathways and defined mechanisms of action have augmented the precision and efficacy of treatment regimens, paving the way for improved patient outcomes in the face of this pervasive malignancy. The present review embarks on a detailed exploration of small-molecule drugs that have secured regulatory approval for breast cancer treatment, emphasizing their clinical applications, synthetic pathways, and distinct mechanisms of action.

show abstract

Section: Abemaciclib Mesylatementioning

confidence: 99%